By Dean Seal


AstraZeneca PLC and Merck & Co. said Friday that long-term follow-up results for trials of its Lynparza treatment showed improved long-term survival for patients with advanced ovarian cancer.

The companies, which jointly developed and commercialized the medication, said a five-year follow-up of one trial showed 65.5% survival in patients treated with Lynparza combined with bevacizumab compared with 48.4% survival in a group given bevacizumab and a placebo.

A seven-year follow-up of another trial showed 67% survival in advanced ovarian cancer patients with BRCA mutations who received Lynparza, compared with 47% in a placebo group.

Susan Galbraith, AstraZeneca's executive vice president of oncology research and development, said the five-year survival rate of newly diagnosed patients with advanced ovarian cancer is 30% to 50%.

"In that context, it is phenomenal to share the long-term overall survival data from both PAOLA-1 and SOLO-1, with two out of three patients still alive in these trials," she said.


Write to Dean Seal at


(END) Dow Jones Newswires

September 09, 2022 08:56 ET (12:56 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Merck Charts.